Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer ...

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also ...

In fact, the success of biosimilars in Europe has given the United ... UnitedHealthcare announced preferred formulary status for Pfizer’s Retacrit, Amgen’s Mvasi, and Amgen’s Kanjinti.

The global biosimilar and biologics market is projected to grow from USD 561.7 billion in 2025 to USD 1,157.4 billion by 2035 ...

Pfizer's Q4 adjusted EPS was $0.63 ... Xeljanz and Oncology biosimilars. Read Next: Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts Fourth-quarter 2024 Comirnaty ...

Pfizer has beaten Wall Street's revenue estimate ... In addition, in early 2025, Teva and Amgen launched biosimilars of Stelara, whose sales account for about 12% of Johnson & Johnson's total ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday ...